Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) and Shineco (NASDAQ:SISI – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.
Insider & Institutional Ownership
4.1% of Shineco shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Shineco shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Supernus Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Shineco has a beta of -1.76, indicating that its stock price is 276% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Supernus Pharmaceuticals | 2 | 1 | 3 | 0 | 2.17 |
| Shineco | 0 | 0 | 0 | 0 | 0.00 |
Supernus Pharmaceuticals presently has a consensus target price of $62.40, indicating a potential upside of 46.24%. Given Supernus Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Supernus Pharmaceuticals is more favorable than Shineco.
Profitability
This table compares Supernus Pharmaceuticals and Shineco’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Supernus Pharmaceuticals | -13.23% | 11.13% | 8.10% |
| Shineco | -380.55% | -79.89% | -33.01% |
Earnings and Valuation
This table compares Supernus Pharmaceuticals and Shineco”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Supernus Pharmaceuticals | $718.95 million | 3.46 | -$38.55 million | ($1.92) | -22.22 |
| Shineco | $9.60 million | 0.00 | -$22.45 million | ($204.00) | -0.00 |
Shineco has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.
Summary
Supernus Pharmaceuticals beats Shineco on 11 of the 14 factors compared between the two stocks.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
About Shineco
Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
